|
Originally published In Press as doi:10.1074/jbc.M808285200 on November 5, 2008
J. Biol. Chem., Vol. 284, Issue 2, 1279-1290, January 9, 2009
SPARC Inhibits Adipogenesis by Its Enhancement of β-Catenin Signaling*
Jing Nie1 and
E. Helene Sage2
From the
Hope Heart Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington 98101
SPARC (secreted protein acidic and rich in cysteine) modulates interactions between cells and extracellular matrix and is enriched in white adipose tissue. We have reported that SPARC-null mice accumulate significantly more fat than wild-type mice and maintain relatively high levels of serum leptin. We now show that SPARC inhibits adipogenesis in vitro. Specifically, recombinant SPARC inhibited (a) adipocyte differentiation of stromal-vascular cells isolated from murine white adipose tissue and (b) the expression of adipogenic transcription factors and adipocyte-specific genes. SPARC induced the accumulation and nuclear translocation of β-catenin and subsequently enhanced the interaction of β-catenin and T cell/lymphoid enhancer factor 1. The activity of integrin-linked kinase was required for the effect of SPARC on β-catenin accumulation as well as extracellular matrix remodeling. During adipogenesis, fusiform preadipocytes change into sphere-shaped adipocytes and convert the extracellular matrix from a fibronectin-rich stroma to a laminin-rich basal lamina. SPARC retarded the morphological changes exhibited by preadipocytes during differentiation. In the presence of SPARC, the deposition of fibronectin was enhanced, and that of laminin was inhibited; in parallel, the expression of 5 integrin was enhanced, and that of 6 integrin was inhibited. Lithium chloride, which enhances the accumulation of β-catenin, also inhibited the expression of 6 integrin. These findings demonstrate a role for SPARC in adipocyte morphogenesis and in signaling processes leading to terminal differentiation.
Received for publication, October 29, 2008
* This work was supported, in whole or in part, by National Institutes of Health Grant R01-GM40711 (to E. H. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1-4.
1 Supported by a postdoctoral fellowship from the American Heart Association, Pacific Mountain Affiliate.
2 To whom correspondence should be addressed: Benaroya Research Institute at Virginia Mason, 1201 9th Ave., Seattle, WA 98101. Tel.: 206-341-1311; Fax: 206-341-1375; E-mail: hsage{at}benaroyaresearch.org.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|